Efficacy and safety of long-term treatment with statins for coronary heart disease: A Bayesian network meta-analysis

2016 ◽  
Vol 254 ◽  
pp. 215-227 ◽  
Author(s):  
Yongbin Lu ◽  
Zhiyuan Cheng ◽  
Yaxue Zhao ◽  
Xiaoyu Chang ◽  
Cynthia Chan ◽  
...  
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Bayesian Network ◽  
Meta Analysis ◽  
Term Treatment ◽  
Efficacy And Safety ◽  
Long Term Treatment

The Frequency of Coronary Heart Disease and Myocardial Infarction in Patients with Rheumatoid Arthritis

1975 ◽  
Author(s):  
S. Czaplicki ◽  
J. Gietka ◽  
K. Sulek
Keyword(s):  
Rheumatoid Arthritis ◽  
Myocardial Infarction ◽  
Coronary Heart Disease ◽  
Heart Disease ◽  
Normal Population ◽  
Term Treatment ◽  
Coronary Risk Factors ◽  
Long Term Treatment ◽  
Adhesion Of Platelets

The frequency of coronary heart disease and myocardial infarction in 500 persons with rheumatoidearthritis (116 men and 384 women) receiving salicylates during long period time were examined. Coronary heart disease in 2 cases (1 man and 1 woman) and myocardial infarction in 1 man were found.On the basis of the age and duration observations the authors discovered that the coefficient morbidity was statistically significant lower than in the same population but without rheumatoid arthritis. The coronary risk factors as hypertenia arterialis, hyper-cholestrolemia and diabetes was less frequent than in normal population too. The cigarettes smoking and obesity were found equally frequent.The authors suggested that long term treatment with acetylsalicylic acid effects inhibition adhesion of platelets and in this way protects before arterial thrombosis and may be artherosclerosis.

scholarly journals The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis

2016 ◽  
Vol 2016 ◽  
pp. 1-11
Author(s):  
Jiao Yang ◽  
Hang Sun ◽  
Qi Liu
Keyword(s):  
Survival Rate ◽  
Liver Failure ◽  
Meta Analysis ◽  
Survival Rates ◽  
Term Treatment ◽  
Chronic Liver ◽  
Efficacy And Safety ◽  
Chronic Liver Failure ◽  
Long Term Treatment

Background.Currently, both of entecavir and lamivudine are effective for patients with HBV-associated acute-on-chronic liver failure (ACLF). However, there is no consensus on the efficacy of entecavir versus lamivudine for patients with HBV-associated ACLF. The aim of the study was to compare the efficacy and safety of entecavir with that of lamivudine for HBV-associated ACLF patients.Methods.Publications on entecavir versus lamivudine in HBV-associated ACLF patients were comprehensively identified. Odds ratio and mean difference were used to measure the effect.Results.Ten studies, totaling 1254 patients, were eligible. No significant differences between the two drugs presented in the 1-, 2-, 3-, or 6-month survival rates. However, after 12 months of treatment, patients prescribed entecavir had a statistically higher survival rate (p=0.008) and lower total bilirubin (p<0.0001) and alanine aminotransferase (p=0.04) levels compared to patients prescribed lamivudine. More patients achieved HBV negative levels when taking entecavir as measured at 1-, 3-, and 12-month time points and had a lower rate of HBV recurrence.Conclusion.While entecavir and lamivudine are both relatively safe and well tolerated, entecavir was more efficacious in terms of survival rate and clinical improvement in long-term treatment. Further prospective randomized controlled trials are needed to validate these results.

Efficacy and safety of long-term treatment with monthly calcifediol soft capsules in vitamin D deficient patients

2021 ◽  
Author(s):  
Jódar Esteban ◽  
Jose Luis Perez-Castrillon ◽  
Dueñas Antonio ◽  
Gonzalo Hernandez ◽  
Nieves Fernandez ◽  
...  
Keyword(s):  
Vitamin D ◽  
Term Treatment ◽  
Efficacy And Safety ◽  
Long Term Treatment

scholarly journals Do antipsychotic drugs lose their efficacy for relapse prevention over time?

2017 ◽  
Vol 211 (3) ◽  
pp. 127-129 ◽  
Author(s):  
Stefan Leucht ◽  
John M. Davis
Keyword(s):  
Relapse Prevention ◽  
Antipsychotic Drugs ◽  
Meta Analysis ◽  
Term Treatment ◽  
First Episode ◽  
Brain Volume Loss ◽  
New Findings ◽  
Long Term Treatment ◽  
Long Term Follow Up

SummaryThere is a debate about long-term treatment of schizophrenia with antipsychotic drugs, with some experts suggesting that these drugs should be discontinued. In this issue, Takeuchi et al demonstrated by a meta-analysis of 11 trials that antipsychotic drugs maintained their efficacy for relapse prevention for 1 year, whereas patients on placebo kept getting worse. We consider these findings in the light of the current discussion about possible dose-related brain volume loss, supersensitivity psychosis, the high variability of results in long-term follow-up studies and recent approaches to discontinue antipsychotics in patients with a first-episode. The new findings speak in favour of continuing antipsychotics at the same dose, at least in patients whose condition is chronic, but the topic is complex.

scholarly journals Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidence

2019 ◽  
Vol 39 (1) ◽  
Author(s):  
Saif Khan ◽  
Raju K. Mandal ◽  
Abdulbaset Mohamed Elasbali ◽  
Sajad A. Dar ◽  
Arshad Jawed ◽  
...  
Keyword(s):  
Gene Polymorphisms ◽  
Meta Analysis ◽  
Term Treatment ◽  
Wild Type ◽  
Severe Problem ◽  
Trial Sequence ◽  
Increased Risk ◽  
Long Term Treatment ◽  
Nat2 Gene

Abstract Hepatotoxicity is a severe problem generally faced by tuberculosis (TB) patients. It is a well-known adverse reaction due to anti-TB drugs in TB patients undergoing long-term treatment. The studies published previously have explored the connection of N-acetyltransferase 2 (NAT2) gene polymorphisms with isoniazid-induced hepatotoxicity, but the results obtained were inconsistent and inconclusive. A comprehensive trial sequence meta-analysis was conducted employing 12 studies comprising 3613 controls and 933 confirmed TB cases using the databases namely, EMBASE, PubMed (Medline) and Google Scholar till December 2017. A significant association was observed with individuals carrying variant allele at position 481C&gt;T (T vs. C: P = 0.001; OR = 1.278, 95% CI = 1.1100–1.484), at position 590G&gt;A (A vs. G: P = 0.002; OR = 1.421, 95% CI = 1.137–1.776) and at position 857G&gt;A (A vs. G: P = 0.0022; OR = 1.411, 95% CI = 1.052–1.894) to higher risk of hepatotoxicity vis-à-vis wild-type allele. Likewise, the other genetic models of NAT2 gene polymorphisms have also shown increased risk of hepatotoxicity. No evidence of publication bias was observed. These results suggest that genetic variants of NAT2 gene have significant role in isoniazid induced hepatotoxicity. Thus, NAT2 genotyping has the potential to improve the understanding of the drug–enzyme metabolic capacity and help in early predisposition of isoniazid-induced hepatotoxicity.

Sign in / Sign up

Export Citation Format

Share Document